Chugai Receives the IR Grand Prix

TOKYO, November 12, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company received the IR Grand Prix at the 2026 IR Award hosted by the Japan Investor Relations Association (JIRA). The Award recognizes companies that demonstrate a profound understanding of the purpose of investor relations, actively engage in IR activities, and achieve outstanding results such as receiving strong support from market participants. A total of 359 companies applied for this year’s Awards, with 13 companies selected: two for the IR Grand Prix, six for the Best IR Award, three for the IR Special Award, and two for the Best IR Award for Encouragement.

The IR Grand Prix is presented to companies that have received the Best IR Award twice within the past 10 years and are deemed worthy of receiving the Best IR Award for a third time. Chugai received the Best IR Award in 2020 and 2023, and this marks the first time the company has been selected for the IR Grand Prix.

The reasons for Chugai’s selection for the IR Grand Prix are as follows: *

• Chugai’s IR activities are of a high standard overall, and the CEO and CFO are deepening their dialogues with investors
• The company’s growth story is clear, and it communicates its challenges and progress toward 2030 with continuity
• Its explanations of R&D projects, which are essential to the valuation of pharmaceutical companies, are highly regarded
• Originality is also evident in areas such as its disclosure of materiality and milestones
• The IR function has strong communication capabilities and organizes a wide variety of events
• The expansion of opportunities for dialogue with outside directors and the enhancement of human capital disclosure have also been highly evaluated

“I am deeply honored that Chugai has been selected for the prestigious IR Grand Prix. We regard dialogue with investors as an important opportunity for management. We have created diverse opportunities for dialogue and have sought to communicate clearly and consistently our growth strategy toward 2030 and the progress we are making, as well as our research and development, which is the source of our value creation. We see this award not only as recognition of our efforts to date, but also as an expression of expectations for our continued evolution. We will continue to further deepen our dialogue with stakeholders, reflect their feedback in our management, and strive to achieve sustainable growth in corporate value,” said Chugai’s President and CEO, Dr. Osamu Okuda.

Chugai aims to become a top innovator in the healthcare industry for advanced and sustainable patient-centric healthcare. Chugai will continue to enhance its IR activities by providing timely and appropriate disclosure of information on our business activities as well as the “creation of shared value” with society, including sustainability initiatives, while actively creating opportunities for dialogue between investors and management.

[Reference]

• Investor Relations: https://www.chugai-pharm.co.jp/english/ir/
• For Individual Investors (in Japanese only): https://www.chugai-pharm.co.jp/ir/individual/
• Chugai’s Value Creation Model: https://www.chugai-pharm.co.jp/english/profile/strategy/valuecreation.html
• Chugai’s Material Issues: https://www.chugai-pharm.co.jp/english/sustainability/core/materiality.html
• R&D: https://www.chugai-pharm.co.jp/english/innovation/rd/
• Presentation Materials: https://www.chugai-pharm.co.jp/english/ir/reports_downloads/presentations.html
• Independent Outside Directors’ Perspectives: https://www.chugai-pharm.co.jp/english/ir/governance/independent_directors_perspectives.html
• Annual Reports: https://www.chugai-pharm.co.jp/english/ir/reports_downloads/annual_reports.html
• People & Culture Report: https://www.chugai-pharm.co.jp/english/sustainability/diversity/people_and_culture_report.html

* The English translation of the reasons for Chugai's selection for the IR Grand Prix was independently prepared by Chugai and therefore do not necessarily match the wording used in JIRA's English news release.